Josh Fink is the Founder and Managing Member of Luma.

Josh is a seasoned investor, leader and philanthropist who has been investing in and supporting multiple companies at the intersection of healthcare and technology since 2016.

Prior to founding Luma Group, Josh was the Founder and Managing Partner of US-based private investment firm, Ophir Holdings, where he played a key role in identifying and investing in high growth potential companies from various sectors in technology, healthcare and natural resources. Throughout his tenure at Ophir Holdings, Josh developed a particular interest in companies that are looking to digitize and disrupt the fields of healthcare and life sciences. Josh is also a founding investor in, and a senior advisor to, Altos Labs and National Resilience.

Previously, Josh was an early investor in and senior advisor to Digital Surgery (acquired by Medtronic). Josh was also the Co-Founder and Managing Partner of Luma Bio-IT SPV, which invested in emerging biotech and medical device companies. Josh also co-founded Compute Health Acquisition Corp with Omar Ishrak – former CEO and Chairman of Medtronic – a special purpose acquisition company (“SPAC”) and served as its Co-CEO.

With over 20 years of experience in private and public investments, Josh has built strong relations with industry experts. Josh has served as a senior advisor to reputable firms, where he was central to capital raising efforts, strategic initiatives and pipeline sourcing.

Josh is a dedicated philanthropist in healthcare, the arts, education and conservation and supports multiple charities around the world. Josh is actively involved in the World Economic Forum and has been dedicated to a number of philanthropic initiatives that include supporting medical institutions and foundation, educational initiatives and access to healthcare. He is also a member of the Fund for the Twenty-First Century and the Committee of Drawings and Prints at the Museum of Modern Art and a member of the Chairman’s Council at the Whitney Museum.

Josh earned his BA from the University of Pennsylvania in 2000.

LinkedIn

Dr. Themasap Khan, PhD, is a co-founder and Partner of Luma Group.

Themasap was previously VP at Civilization Ventures, a life sciences and health-tech venture firm. He joined the fund shortly after its inception and helped grow the firm into an early-stage biotech powerhouse, backing companies from Series Seed to IPO. Civilization was often the first-money and the lead investor in early-stage biotech companies. Themasap was involved in helping run the firm’s functions across scientific strategy, operations, and business development, and he co-ran the firm’s pioneering Fellowship program.

Themasap has been an author on multiple scientific publications in Nature, Cell and other scientific journals. His research was focused on cancer biology, neuroscience and genomics – with a combined 10+ years spent in life science research labs.

Themasap received his Ph.D. from Stanford University where he was an NSF Graduate Research Fellow and Stanford Graduate Fellow. Themasap earned his BS in Neuroscience from New York University.

LinkedIn

Dr. Jamie Kasuboski, PhD, is a Partner & Head of Research at Luma Group.

Jamie has spent 15 years in biomedical research and over a decade of expertise in the Biotech and Pharmaceutical sectors. Dr. Kasuboski has been involved in investments across more than 18 companies, ranging from pre-clinical to clinical development stages. These companies have successfully raised additional capital and established several industry partnerships. Previously, Jamie served as Vice President at OMX Ventures, RA Capital and Boehringer Ingelheim’s Venture Fund. He has experience on preclinical and clinical-stage therapeutic investments and early-stage research tools.

Jamie’s background in primary research is extensive, spanning over a decade in both pharmaceuticals and academia. Jamie holds a Ph.D. in Cell and Molecular Biology from the University of Notre Dame. Jamie earned his BS in Biology with a Chemistry minor in 2002 from Hillsdale College in Michigan.

LinkedIn

Bill Ryan joined Luma Group in July 2024 as Chief Financial Officer. He previously was Director, Head of Funding Accounting – Private and Public markets at The Rohatyn Group, a global asset manager specializing in emerging markets and real assets. Prior to joining The Rohatyn Group in 2020, Mr. Ryan held positions at Prospect Capital Corporation, Centerbridge Partners L.P. and Fortress Investment Group, LLC.

Mr. Ryan began his career in 2005 in Ernst & Young LLP’s financial services office. Mr. Ryan acts as a strategic advisor on fundraising, fund performance reporting, and all fund operations areas including budget, forecast, liquidity projection, vendor management, accounting and financial reporting, HR and compliance.

Mr. Ryan graduated cum laude with a BS in Accounting from Fairfield University and is a Certified Public Accountant in the state of New York.

LinkedIn

John Gomez is an associate on the investment team at Luma Group and focuses on therapeutics, diagnostic and medical devices. Previously, John worked in life science strategy consulting at ClearView Healthcare Partners where he engaged with leading pharma, biotech and private equity clients. During his time at ClearView he focused on scientific & commercial M&A due diligence, commercial strategy and portfolio strategy for pre-clinical and clinical stage assets.

John graduated with honors from Johns Hopkins University with a degree in Public Health.

LinkedIn

Dr. Ebright is a Science Fellow at Luma Group and an Oncology Fellow at Dana-Farber Cancer Institute and Mass General Brigham. He earned his medical and graduate degrees from Harvard Medical School and completed his internal medicine residency at Massachusetts General Hospital. In 2020, he was named to the Forbes 30 Under 30 Science list, highlighting his achievements in advancing oncology. His work focuses on innovative cancer treatments, and he is dedicated to improving patient outcomes through cutting-edge research and clinical excellence.

Beyond his medical training, Dr. Ebright is deeply committed to the collaborative nature of oncology, recognizing the critical role of mentorship and teamwork in driving progress. He’s worked at other leading firms as a consultant, including Third Rock and Nextech. His expertise spans both research and clinical practice, with a passion for developing new therapies that can transform the landscape of cancer treatment.

LinkedIn

Dr. Mishra is a Clinical Advisor, guiding Luma Group’s team through investments and diligence processes. Dr. Mishra is passionate about serving underprivileged populations, so he established his clinical base at Montefiore Medical Center, one of the largest healthcare groups in the Bronx, where he also served as Site Director for the Hospital Medicine program and currently assistant professor of Medicine at Albert Einstein College of Medicine. 

Beyond patient care, Dr. Mishra is dedicated to strengthening relationships between hospitals, community organizations and patients. His work extends across both domestic and international settings. In India, he launched a public healthcare initiative to combat the spread of communicable diseases in Uttar Pradesh. His global contributions also include advising on the expansion of emergency medical response systems and serving as a healthcare advisor to international organizations.

LinkedIn

Richie Santry is the Chief of Staff at Luma Group, supporting senior leadership and the investment team across a variety of initiatives. Prior to joining the team, Richie worked at Nomura on the Equity Capital Markets team in the Investment Banking Division.

Richie graduated from Dartmouth College with a double major in Government and Environmental Studies and was a four-year member of the men’s heavyweight rowing team.

LinkedIn

Tamara Young has lived and worked across three continents, bringing a global perspective to her career. She has contributed to renowned global organizations such as Etihad Airways and Carnival Cruise Line. Tamara ensures efficient operations and supports senior leadership in achieving their strategic goals.

Tamara holds a bachelor’s degree in journalism from the University of Novi Sad, Serbia.